Combination therapy using siRNA nanocompelex and PD-L1 inhibitor for alcoholic liver fibrosis

点击翻译按钮获取中文摘要

Project Summary The purpose of this administrative supplement application is to purchase a SpectraMax iD5 Multi- Mode Microplate Reader with bottom luminescence read mode. The SpectraMax iD5 Multi-Mode Microplate Reader is a five-mode reader that measures absorbance, fluorescence, luminescence, time- resolved fluorescence (TRF), and tunable fluorescence polarization (FP) for a broad range of applications. We currently have a 15-year-old plate reader (SpectraMax Gemini XPS), which is not working properly. In addition, our plate reader is an old model, which cannot be used for protein binding assay using HTRF. We have completed all the work in Aim 1 and most of the work in Aim 2 of the parent grant. For the rest studies in Aims 2 and 3, we will heavily depend on the use of a multi-mode microplate reader to frequently conduct protein binding assay, cellular uptake study, immunoassay, cell viability assay, ELISA, BCA assay, ALT/AST assay, western blot, and cell proliferation assay. Therefore, there is an urgent need to purchase the new SpectraMax iD5 plate reader for our research. The acquisition of the Multi-Mode Microplate Reader will significantly enhance our capability to make good progress in the research. This is essential for the success of the proposed animal studies to evaluate the stability, biodistribution, and activity of the PCBP2 siRNA nanocomplex in combination with the anti-PD-L1 inhibitor in a rat model of liver fibrosis.